Literature DB >> 12570745

Cancer and phase II drug-metabolizing enzymes.

S A Sheweita1, A K Tilmisany.   

Abstract

Cancer development results from the interaction between genetic factors, the environment, and dietary factors have been identified as modulators of carcinogenesis process. The formation of DNA adducts is recognized as the initial step in chemical carcinogenesis. Accordingly, blocking DNA adducts formation would be the first line of defense against cancer caused by carcinogens. Glutathione-S-transferases inactivate chemical carcinogens into less toxic or inactive metabolite through reduction of DNA adducts formation. There are many different types of glutathione S-transferase isozymes. For example, GST delta serves as a marker for hepatotoxicity in rodent system, and also plays an important role in carcinogen detoxification. Therefore, inhibition of GST activity might potentiate the deleterious effects of many environmental toxicants and carcinogens. In addition, approximately half of the population lacks GST Mu expression. Epidemiological evidence showed that persons possessing this genotype are predisposed to a number of cancers including breast, prostate, liver and colon cancers. In addition, individual risk of cancer depends on the frequency of mutational events in target oncogenes and tumor suppressor genes which could lead to loss of chromosomal materials and tumor progression. The most frequent genetic alteration in a variety of human malignant tumors is the mutation of the coding sequence of the p53 tumor suppressor gene. O(6)-alkylguanine in DNA leads to very high rates of G:C deltaA:T transitions in p53 gene. These alterations will modulate the expression of p53 gene and consequently change DNA repair, cell division, and cell death by apoptosis. Also, changes in the expression of BcI-2 gene results in extended viability of cells by over-riding programmed cell death (apoptosis) induced under various conditions. The prolonged life-span increases the risk of acquiring genetic changes resulting in malignant transformation. In addition, a huge variety of food ingredients have been shown to affect cell proliferation rates. They, therefore, may either reduce or increase the risk of cancer development and progression. For example, it has been found that a high intake of dietary fat accelerates the development of breast cancer in animal models. Certain diets have been suggested to act as tumor promoters also in other types of cancer such as colon cancer, where high intake of fat and phosphate have been linked to colonic hyper-proliferation and colon cancer development. Different factors such as oncogenes, aromatic amines, alkylating agents, and diet have a significant role in cancer induction. Determination of glutathione S-transferase isozymes in plasma or serum could be used as a biomarker for cancer in different organs and could give an early detection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12570745     DOI: 10.2174/1389200033336919

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  26 in total

Review 1.  Cytochrome P450 humanised mice.

Authors:  Frank J Gonzalez
Journal:  Hum Genomics       Date:  2004-05       Impact factor: 4.639

2.  Biomedical Technologies for in vitro Screening and Controlled Delivery of Neuroactive Compounds.

Authors:  John P Frampton; Michael L Shuler; William Shain; Matthew R Hynd
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2008

3.  A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR1I2 genes and lymphoma risk.

Authors:  Daniele Campa; Katja Butterbach; Susan L Slager; Christine F Skibola; Silvia de Sanjosé; Yolanda Benavente; Nikolaus Becker; Lenka Foretova; Marc Maynadie; Pierluigi Cocco; Anthony Staines; Rudolf Kaaks; Paolo Boffetta; Paul Brennan; Lucia Conde; Paige M Bracci; Neil E Caporaso; Sara S Strom; Nicola J Camp; James R Cerhan; Federico Canzian; Alexandra Nieters
Journal:  Int J Cancer       Date:  2011-11-28       Impact factor: 7.396

4.  Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.

Authors:  Eek Joong Park; Jun Hee Lee; Guann-Yi Yu; Guobin He; Syed Raza Ali; Ryan G Holzer; Christoph H Osterreicher; Hiroyuki Takahashi; Michael Karin
Journal:  Cell       Date:  2010-01-22       Impact factor: 41.582

5.  Benzo[a]pyrene (BP) DNA adduct formation in DNA repair-deficient p53 haploinsufficient [Xpa(-/-)p53(+/-)] and wild-type mice fed BP and BP plus chlorophyllin for 28 days.

Authors:  Kaarthik John; M Margaret Pratt; Frederick A Beland; Mona I Churchwell; Gail McMullen; Ofelia A Olivero; Igor P Pogribny; Miriam C Poirier
Journal:  Carcinogenesis       Date:  2012-07-24       Impact factor: 4.944

Review 6.  Redox regulation in cancer: a double-edged sword with therapeutic potential.

Authors:  Asha Acharya; Ila Das; Des Chandhok; Tapas Saha
Journal:  Oxid Med Cell Longev       Date:  2010 Jan-Feb       Impact factor: 6.543

Review 7.  Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Authors:  Joao Tomé-Carneiro; Mar Larrosa; Antonio González-Sarrías; Francisco A Tomás-Barberán; María Teresa García-Conesa; Juan Carlos Espín
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

8.  GSTT1, GSTM1 and CYP2E1 genetic polymorphisms in gastric cancer and chronic gastritis in a Brazilian population.

Authors:  Jucimara Colombo; Andréa Regina Baptista Rossit; Alaor Caetano; Aldenis Albaneze Borim; Durval Wornrath; Ana Elizabete Silva
Journal:  World J Gastroenterol       Date:  2004-05-01       Impact factor: 5.742

9.  Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.

Authors:  Federico Innocenti; Jacqueline Ramírez; Jennifer Obel; Julia Xiong; Snezana Mirkov; Yi-Lin Chiu; David A Katz; Robert A Carr; Wei Zhang; Soma Das; Araba Adjei; Ann M Moyer; Pei Xian Chen; Andrew Krivoshik; Diane Medina; Gary B Gordon; Mark J Ratain; Leonardo Sahelijo; Richard M Weinshilboum; Gini F Fleming; Anahita Bhathena
Journal:  Pharmacogenet Genomics       Date:  2013-07       Impact factor: 2.089

10.  GSTP1, GSTM1, and GSTT1 genetic polymorphisms in patients with cryptogenic liver cirrhosis.

Authors:  Shahrokh Mohammadzadeh Ghobadloo; Bahram Yaghmaei; Valery Bakayev; Hossein Goudarzi; Babak Noorinayer; Farhad Haghighi Rad; Saeed Samiy; Sohrab Aghabozorghi; Mohammad Reza Zali
Journal:  J Gastrointest Surg       Date:  2004 May-Jun       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.